Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Eye Care

Journal Scan / Research · September 06, 2023

Outcomes of Brolucizumab Therapy in Patients With Neovascular AMD

Ophthalmology

 

Additional Info

Ophthalmology
One-Year Brolucizumab Outcomes in Neovascular Age-Related Macular Degeneration from a Large United States Cohort in the IRIS® Registry
Ophthalmology 2023 Sep 01;130(9)937-946, MW MacCumber, CC Wykoff, H Karcher, E Adiguzel, SB Sinha, S Vishwakarma, A LaPrise, F Igwe, R Freitas, MS Ip, MA Zarbin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading